We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The potential of liposome–encapsulated ciprofloxacin as a tularemia therapy.
- Authors
Hamblin, Karleigh A.; Wong, Jonathan P.; Blanchard, James D.; Atkins, Helen S.
- Abstract
Liposome-encapsulation has been suggested as method to improve the efficacy of ciprofloxacin against the intracellular pathogen, Francisella tularensis. Early work with a prototype formulation, evaluated for use against the F. tularensis live vaccine strain, showed that a single dose of liposomal ciprofloxacin given by the intranasal or inhalational route could provide protection in a mouse model of pneumonic tularemia. Liposomal ciprofloxacin offered better protection than ciprofloxacin given by the same routes. Liposomal ciprofloxacin has been further developed by Aradigm Corporation forPseudomonas aeruginosa infections in patients with cystic fibrosis and non-cystic fibrosis bronchiectasis. This advanced development formulation is safe, effective and well tolerated in human clinical trials. Further evaluation of the advanced liposomal ciprofloxacin formulation against the highly virulent F. tularensis Schu S4 strain has shown that aerosolized CFI (Ciprofloxacin encapsulated in liposomes for inhalation) provides significantly better protection than oral ciprofloxacin. Thus, liposomal ciprofloxacin is a promising treatment for tularemia and further research with the aim of enabling licensure under the animal rule is warranted.
- Subjects
TULAREMIA; QUINOLONE antibacterial agents; CIPROFLOXACIN; GRAM-negative bacterial diseases; FRANCISELLA tularensis; MEDICAL sciences
- Publication
Frontiers in Cellular & Infection Microbiology, 2014, Vol 4, p1
- ISSN
2235-2988
- Publication type
Article
- DOI
10.3389/fcimb.2014.00079